Anzeige
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News
100% seit April - und trotzdem erst der Anfang? Kupfer wird zum Turbo-Rohstoff des Jahres!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QAME | ISIN: US92556V1061 | Ticker-Symbol: VIA
Tradegate
22.07.25 | 21:52
7,878 Euro
+3,52 % +0,268
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
S&P 500
1-Jahres-Chart
VIATRIS INC Chart 1 Jahr
5-Tage-Chart
VIATRIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,7707,83222.07.
7,8087,90822.07.

Aktuelle News zur VIATRIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoVTRS Down on Late-Stage Study Failure of Eye Disease Drug12
FrViatris Hits Snag In Eye Drug Study-Phase 3 Plans Under Review5
FrViatris stock unchanged as Goldman maintains Neutral rating on trial miss9
FrWhy Is Viatris Stock Falling In Pre-market?343WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% ophthalmic ointment...
► Artikel lesen
FrViatris down on late-stage trial setback for eye disorder therapy4
FrViatris-Aktie fällt nach verfehltem Studienziel bei Blepharitis-Behandlung14
FrViatris stock falls after Phase 3 blepharitis study misses endpoint5
VIATRIS Aktie jetzt für 0€ handeln
FrViatris: Medikament gegen Blepharitis verfehlt primären Studienendpunkt12
FrViatris blepharitis treatment fails to meet primary endpoint in trial3
FrViatris Inc.: Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis126PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled...
► Artikel lesen
15.07.Viatris Certified as a Great Place to Work in Canada18
12.07.Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT16
09.07.J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug32
27.06.Viatris says second phase 3 trial of blurred vision drug meets goal6
27.06.Viatris gains China approval for Yupelri to treat COPD15
26.06.Viatris Eye Drops Data Shows Promise For Blurred Near Vision10
26.06.Viatris Reports Positive Data From Presbyopia Study343WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus...
► Artikel lesen
26.06.Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China317WASHINGTON (dpa-AFX) - Theravance Biopharma, Inc. (TBPH) announced that Viatris Inc. has secured regulatory approval from China's National Medical Products Administration for YUPELRI inhalation...
► Artikel lesen
26.06.Theravance higher as China approves Viatris-partnered COPD therapy5
26.06.Viatris Inc.: Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia226MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety...
► Artikel lesen
Weiter >>
157 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,8